Drägerwerk AG & Co. KGaA (pref) (DRW3) - Net Assets
Based on the latest financial reports, Drägerwerk AG & Co. KGaA (pref) (DRW3) has net assets worth €1.47 Billion EUR (≈ $1.71 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.99 Billion ≈ $3.49 Billion USD) and total liabilities (€1.52 Billion ≈ $1.78 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Drägerwerk AG & Co. KGaA (pref) (DRW3) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.47 Billion |
| % of Total Assets | 49.09% |
| Annual Growth Rate | 5.92% |
| 5-Year Change | 48.65% |
| 10-Year Change | 62.46% |
| Growth Volatility | 6.36 |
Drägerwerk AG & Co. KGaA (pref) - Net Assets Trend (2013–2024)
This chart illustrates how Drägerwerk AG & Co. KGaA (pref)'s net assets have evolved over time, based on quarterly financial data. Also explore Drägerwerk AG & Co. KGaA (pref) balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Drägerwerk AG & Co. KGaA (pref) (2013–2024)
The table below shows the annual net assets of Drägerwerk AG & Co. KGaA (pref) from 2013 to 2024. For live valuation and market cap data, see Drägerwerk AG & Co. KGaA (pref) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.54 Billion ≈ $1.80 Billion |
+9.05% |
| 2023-12-31 | €1.41 Billion ≈ $1.65 Billion |
+6.81% |
| 2022-12-31 | €1.32 Billion ≈ $1.54 Billion |
+4.68% |
| 2021-12-31 | €1.26 Billion ≈ $1.47 Billion |
+21.93% |
| 2020-12-31 | €1.03 Billion ≈ $1.21 Billion |
-3.95% |
| 2019-12-31 | €1.08 Billion ≈ $1.26 Billion |
-0.40% |
| 2018-12-31 | €1.08 Billion ≈ $1.26 Billion |
+1.15% |
| 2017-12-31 | €1.07 Billion ≈ $1.25 Billion |
+6.46% |
| 2016-12-31 | €1.00 Billion ≈ $1.17 Billion |
+6.09% |
| 2015-12-31 | €945.93 Million ≈ $1.11 Billion |
+5.50% |
| 2014-12-31 | €896.61 Million ≈ $1.05 Billion |
+9.88% |
| 2013-12-31 | €815.97 Million ≈ $953.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Drägerwerk AG & Co. KGaA (pref)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 100.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.18 Billion | 77.15% |
| Other Components | €350.77 Million | 22.85% |
| Total Equity | €1.54 Billion | 100.00% |
Drägerwerk AG & Co. KGaA (pref) Competitors by Market Cap
The table below lists competitors of Drägerwerk AG & Co. KGaA (pref) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Reysas Tasimacilik ve Lojistik Ticaret AS
IS:RYSAS
|
$895.90 Million |
|
Shanghai Xinhua Media Co Ltd
SHG:600825
|
$895.99 Million |
|
Beyondsoft Corp
SHE:002649
|
$896.80 Million |
|
Hunan Tyen Machinery Co Ltd A
SHG:600698
|
$897.08 Million |
|
Zhejiang Oceanking Development Co Ltd
SHG:603213
|
$895.74 Million |
|
Xiamen 35Com Tech
SHE:300051
|
$895.50 Million |
|
Pantoro Gold Ltd
AU:PNR
|
$895.30 Million |
|
NCR Voyix Corporation
NYSE:VYX
|
$895.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Drägerwerk AG & Co. KGaA (pref)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,406,779,000 to 1,535,151,000, a change of 128,372,000 (9.1%).
- Net income of 124,408,000 contributed positively to equity growth.
- Dividend payments of 33,158,000 reduced retained earnings.
- Share repurchases of 2,535,000 reduced equity.
- Other factors increased equity by 39,657,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €124.41 Million | +8.1% |
| Dividends Paid | €33.16 Million | -2.16% |
| Share Repurchases | €2.54 Million | -0.17% |
| Other Changes | €39.66 Million | +2.58% |
| Total Change | €- | 9.13% |
Book Value vs Market Value Analysis
This analysis compares Drägerwerk AG & Co. KGaA (pref)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.48x to 1.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €60.08 | €89.10 | x |
| 2018-12-31 | €60.77 | €89.10 | x |
| 2019-12-31 | €60.52 | €89.10 | x |
| 2020-12-31 | €55.06 | €89.10 | x |
| 2021-12-31 | €67.16 | €89.10 | x |
| 2022-12-31 | €70.26 | €89.10 | x |
| 2023-12-31 | €74.99 | €89.10 | x |
| 2024-12-31 | €81.83 | €89.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Drägerwerk AG & Co. KGaA (pref) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.10%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.69%
- • Asset Turnover: 1.09x
- • Equity Multiplier: 2.02x
- Recent ROE (8.10%) is below the historical average (8.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.70% | 5.03% | 1.15x | 2.54x | €38.14 Million |
| 2014 | 11.71% | 4.30% | 1.09x | 2.50x | €15.32 Million |
| 2015 | 3.56% | 1.29% | 1.13x | 2.45x | €-60.86 Million |
| 2016 | 8.20% | 3.25% | 1.09x | 2.31x | €-18.07 Million |
| 2017 | 9.23% | 3.83% | 1.09x | 2.21x | €-8.24 Million |
| 2018 | 3.18% | 1.32% | 1.08x | 2.23x | €-73.57 Million |
| 2019 | 3.10% | 1.20% | 1.08x | 2.39x | €-74.13 Million |
| 2020 | 24.22% | 7.34% | 1.03x | 3.20x | €146.87 Million |
| 2021 | 12.24% | 4.63% | 1.05x | 2.52x | €28.24 Million |
| 2022 | -4.90% | -2.12% | 0.98x | 2.36x | €-196.37 Million |
| 2023 | 7.85% | 3.27% | 1.09x | 2.20x | €-30.24 Million |
| 2024 | 8.10% | 3.69% | 1.09x | 2.02x | €-29.11 Million |
Industry Comparison
This section compares Drägerwerk AG & Co. KGaA (pref)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $934,837,026
- Average return on equity (ROE) among peers: -23.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Drägerwerk AG & Co. KGaA (pref) (DRW3) | €1.47 Billion | 14.70% | 1.04x | $895.84 Million |
| HeraMED Limited (1I4) | $2.59 Million | -168.10% | 0.60x | $26.40 Million |
| Medtronic PLC (2M6) | $841.50 Million | 23.43% | 0.53x | $102.18 Billion |
| Peijia Medical Limited (4WO) | $2.04 Billion | -11.08% | 0.32x | $403.65 Million |
| AVITA Medical Inc (51KB) | $20.86 Million | -118.03% | 0.23x | $172.49 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.22 Billion | -2.23% | 0.20x | $107.57 Million |
| MODULIGHT OY EO 1 (78W) | $44.68 Million | -10.30% | 0.10x | $43.97 Million |
| ACOTEC SCIEN.H. DL-00001 (7W3) | $1.28 Billion | 5.50% | 0.11x | $377.38 Million |
| LIFETECH SCI.DL-00000125 (81X) | $2.53 Billion | 11.56% | 0.26x | $893.41 Million |
| ORTOMA AB B (82Y) | $142.72 Million | -13.45% | 0.13x | $26.39 Million |
| COPLAND ROAD CAPITAL NEW (A2P) | $223.54 Million | 46.04% | 1.19x | $594.67 Million |
About Drägerwerk AG & Co. KGaA (pref)
Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, devices, and services for the medical division, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas m… Read more